Daniel Mytelka has spent the last 25 years looking for value at the border between science and business in the biopharma industry. Originally trained in the biosciences (AB Molecular Biology from Princeton, PhD Genetics from UC Berkeley), he received an MBA from the University of Chicago before spending almost 20 years at Eli Lilly in diverse roles including strategy/portfolio management, business development and market access. After a stint as director of simulation and policy for the MIT Center for Biomedical Innovation, he joined Diviner where he is the Head of Methodology.

© 2022 BioFutureTM. All Rights Reserved

Produced by